Table 1.
Patient Characteristics
| Characteristic | N = 12 |
|---|---|
| Age (years) | 55 (range 46–73 years) |
| Gender | |
| Male | 8 (67%) |
| Female | 4 (33%) |
| Tumor location | |
| Temporal | 5 (42%) |
| Frontal | 4 (33%) |
| Parietal | 3 (25%) |
| Gross total resection | 10 (83%) |
| EGFR amplifications | 2 (17%) |
| IDH1 R132H mutation | 1 (8%) |
| Additional chemotherapy | |
| Aflibercept (VEGF trap) | 1 (8%) |
| Ofranergene obadenovec (VB-111) | 1 (8%) |
| Dendritic cell vaccine (DCvax-L) | 2 (17%) |
| Bevacizumab treatment | |
| Treatment length | 9.5 (range 4–24 weeks) |
| Progression-free survival after treatment | 6.4 (range 1–13 months) |
| Time to surgery after treatment | 7.7 (range 3–13 months) |
| Survival after treatment | 15.5 (range 5–53 months) |
| Survival from the initial diagnosis | 39 (range 10–147 months) |